Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background: Till date, there is no Cochrane meta-analysis available which has analyzed efficacy and safety of tirzepatide in type-2 diabetes. This meta-analysis was undertaken to address this knowledge gap. Methods: Electronic databases were searched for randomized controlled trials (RCTs) involving people with diabetes receiving tirzepatide compared to a placebo/active comparator. Primary outcome was to evaluate changes in HbA1c. Secondary outcomes were to evaluate alterations in blood–glucose, glycemic targets, weight, lipids, and adverse events. Results: From 34 articles initially screened, data from six RCTs involving 3484 patients were analyzed. Over 12–52 weeks, individuals receiving tirzepatide had significantly greater lowering of HbA1c [mean difference (MD) = -0.75% (95% confidence interval (CI): -1.05 to -0.45); P < 0.01; I 2 = 100%], fasting glucose [MD = -0.75 mmol/L (95% CI: -1.05 to– -0.45); P < 0.01; I 2 = 100%], 2-h post-prandial-glucose [MD = -0.87 mmol/L (95% CI: -1.12 to -0.61); P < 0.01; I 2 = 99%], weight [MD = -8.63 kg (95% CI: -12.89 to -4.36); P < 0.01; I 2 = 100%], body mass index [MD = -1.80 kg/m 2 (95% CI: -2.39 to -1.21); P < 0.01; I 2 = 99%], and waist circumference [MD = -4.43 cm (95% CI: -5.31 to -3.55); P < 0.01; I 2 = 95%] as compared to dulaglutide, semaglutide, degludec, or glargine. Patients receiving tirzepatide had higher odds of achieving HbA1c <6.5% compared to active controls [odds ratio (OR) = 4.39 (95% CI: 2.44–7.92); P < 0.01; I 2 = 90%]. Tirzepatide use had significantly higher odds of weight loss >5% [OR = 19.18 (95% CI: 2.34–157.17); P < 0.01; I 2 = 99%], >10% [OR = 21.40 (95% CI: 2.36–193.94); P < 0.01; I 2 = 98%], and >15% [OR = 32.84 (95% CI: 2.27–474.33); P = 0.01; I 2 = 96%] compared to active-control group. Treatment-emergent adverse events [risk ratio (RR) = 1.43 (95% CI: 1.14–1.80); P < 0.01; I 2 = 40%] and severe adverse events [RR = 1.00 (95% CI: 0.64–1.57); P = 1.00; I 2 = 49%] were not different. High data heterogeneity and the presence of publication bias limits the grading of current data from “moderate to low.” Conclusion: Tirzepatide has impressive glycemic efficacy and weight-loss data over 1-year clinical use. The need for higher grade, long-term efficacy, and safety data remains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305 · cited 3×
“Publication bias was assessed by plotting Funnel Plots.[10] The presence of one or more of the smaller studies outside inverted funnel plot signifies significant publication bias.”
MethodInfluentialTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 12×
“Since papers by Pirro et al.,[18] Wilson et al.,[6] Hartman et al.,[19] and Thomas et al.[20] were post‑hoc analysis of original RCT by Frias et al.[12](2018); in our analysis, the results from these four papers have been pooled with data from Frias et al. (2018) to avoid duplicity.”
BackgroundMethodInfluentialCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 6×
“[4] This lead to development of tirzepatide, a novel dual GIP/ GLP‑1 receptor agonist (twincretin), formulated as a synthetic peptide containing 39‑amino acids, based on the native GIP.”
BackgroundInfluentialFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 11×
“Since papers by Pirro et al.,[18] Wilson et al.,[6] Hartman et al.,[19] and Thomas et al.[20] were post‑hoc analysis of original RCT by Frias et al.[12](2018); in our analysis, the results from these four papers have been pooled with data from Frias et al. (2018) to avoid duplicity.”
BackgroundMethodInfluentialLudvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639 · cited 7×
“The durations of follow‑up in the studies by Frias et al. (2018),[12] Frias et al. (2020),[13] Frias et al. (2021),[14] Rosenstock et al. (2021),[15] Ludvik et al. (2021),[16] and del Prato et al. (2021)[17] were 26, 12, 40, 40, 52, and 52 weeks respectively.”
BackgroundMethodInfluentialTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 5×
“T2DM is characterized by loss of insulinotropic property of GIP along with loss of glucagonostatic in the hyperglycemic state (GIP resistance).[2] Some studies have even documented glucagonotropic property of GIP during hyperglycemia, which is otherwise normally seen only during normoglycemia or hypoglycemia.”
BackgroundInfluentialNauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503 · cited 3×
“[1] Unlike GLP‐1, GIP has glucagonostatic in the hyperglycemic state, but glucagonotropic property during normoglycemic and hypoglycemic state.[1] Glucagon is known to prevent hypoglycemia.”
BackgroundInfluentialPublication and related biases.
Song, Eastwood, Gilbody, Duley, & Sutton (2000) · Health Technology Assessment · doi:10.3310/hta4100 · Cited by 427
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Hartman, M. L., Sanyal, A. J., Loomba, R., Wilson, J. M., Nikooienejad, A., Bray, R., Karanikas, C. A., Duffin, K. L., Robins, D. A., & Haupt, A. (2020) · Diabetes Care · doi:10.2337/dc19-1892 · Cited by 351 · cited 11×
“Since papers by Pirro et al.,[18] Wilson et al.,[6] Hartman et al.,[19] and Thomas et al.[20] were post‑hoc analysis of original RCT by Frias et al.[12](2018); in our analysis, the results from these four papers have been pooled with data from Frias et al. (2018) to avoid duplicity.”
BackgroundMethodInfluential
Cited by
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review
Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V. (2022) · Molecules · doi:10.3390/molecules27134315 · Cited by 208
Tirzepatide: A Systematic Update
Forzano, I., Varzideh, F., Avvisato, R., Jankauskas, S. S., Mone, P., & Santulli, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314631 · Cited by 118
“Similarly, Dutta and colleagues [79] found that individuals receiving Tirzepatide for over 1 year had a significantly greater lowering of HbA1c (−0.”
Adverse Events Related to Tirzepatide
Mishra, R., Raj, R., Elshimy, G., Zapata, I., Kannan, L., Majety, P., Edem, D., & Correa, R. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad016 · Cited by 110
Dual GIP/GLP-1 receptor agonists: new advances for treating type-2 diabetes
Scheen, A. J. (2023) · Annales d'Endocrinologie · doi:10.1016/j.ando.2022.12.423 · Cited by 63
Metadata
- Authors
- Dutta, D., Surana, V., Singla, R., Aggarwal, S., & Sharma, M.
- Venue
- Indian Journal of Endocrinology and Metabolism
- Publisher
- Medknow
- Published
- 2021-11
- Volume
- 25
- Issue
- 6
- Pages
- 475-489
- ISSN
- 2230-8210 (ISSN-L)
- 2230-9500
- OpenAlex
- W4213225335
- Cited by
- 60
- References
- 12
- FWCI
- 6.85
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis. https://app.cochat.ai/papers/10.4103/ijem.ijem_423_21
- The paper
- Dutta, D., Surana, V., Singla, R., Aggarwal, S., & Sharma, M. (2021). Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis. Indian Journal of Endocrinology and Metabolism. https://doi.org/10.4103/ijem.ijem_423_21
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.